<DOC>
	<DOCNO>NCT00858182</DOCNO>
	<brief_summary>A major challenge peritoneal dialysis ( PD ) therapy development glucose-sparing strategy able provide efficacious ultrafiltration ( UF ) profile . Study hypothesis evaluate possibility formulate PD solution contain xylitol L-carnitine osmotic agent partially replace glucose .</brief_summary>
	<brief_title>Study Safety Efficacy New Peritoneal Dialysis Solutions</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Dialysis Solutions</mesh_term>
	<criteria>Age ≥18 year ; Diagnosis ESRD treat least three month CAPD , state medical staff center ; CAPD treatment 2.27 % glucose solution nocturnal exchange ; Stable clinical condition within four week screen period , certified medical/surgical history , physical examination laboratory exploration ; Hemoglobin level ≥9g/dL ; Residual diuresis ≤800mL ; Absence acute peritonitis and/or peritoneal catheter infection ( either exit site subcutaneous tunnel ) episode within three month selection ; Stable peritoneal permeability , confirm PET 0.50 0.81 previous three month day 0 screening period ; Total urea Kt/V &gt; 1.5 per week control previous three month day 0 screening period and/or minimal total creatinine clearance 45 liter/week control previous three month day 0 screening period ; 1 To understand sign inform consent form . For patient include Group B , follow criterion must fulfil : Be treat Extraneal ( nocturnal exchange bag solution ) least 1 month Be treat 2 3 diurnal exchange bag solution ( solution bags 1.36 % 2.27 % glucose ) one nocturnal exchange bag solution ( Extraneal ) History alcohol drug abuse last six month selection study ; Androgen therapy last six month selection ; Active infection ; History congestive heart failure stage III IV NYHA ; History major cardiovascular event like stroke , acute myocardial infarction , coronary arterial revascularization procedure last three month selection ; Clinically relevant cardiac arrhythmia ; Clinically relevant abnormality functional hepatic test ; Therapy Lcarnitine derivative last three month selection ; Pregnancy , lactate woman female subject childbearing potential use effective method contraception ; Presence relevant chronic medical condition could suggest exclusion patient study could interfere assessment study parameter , especially life expectation less one year ; Participation another clinical study within past month ; Known suppose allergic reaction Lcarnitine xylitol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>L-Carnitine</keyword>
	<keyword>Xylitol</keyword>
	<keyword>Peritoneal Dialysis</keyword>
</DOC>